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Summary
Objectives: To determine prevalence, risk factors, and simple identification algorithms for HIV,
hepatitis B, and hepatitis C co-infection; factors that may predispose for anti-tuberculosis
therapy-induced hepatotoxicity.
Methods: We recruited 300 individuals at in-patient tuberculosis hospitals in three cities in
Georgia, administered a behavioral questionnaire, and tested for antibody to HIV, hepatitis C
(HCV), hepatitis B core antigen (anti-HBc), and the hepatitis B surface antigen (HBsAg).
Results: Of the individuals tested, 0.7% were HIV positive, 4.3% were HBsAg positive, 8.7% were
anti-HBc positive, and 12.0% were HCV positive. In multivariable analysis, a history of blood
transfusion, injection drug use, and prison were significant independent risk factors for HCV,
while a history of blood transfusion, injection drug use, younger age at sexual debut, and a high
number of sex partners were significant risk factors for HBV. Three-questionnaire item algorithms
predicted HCV serostatus 74.1% of the time and HBV serostatus 85.2% of the time.
Conclusions: Treatment of tuberculosis patients in resource-limited countries with concurrent
epidemics of HCV, HBV, and HIV may be associated with significant hepatotoxicity. Serologic
screening of tuberculosis patients for HBV, HCV, and HIVor using behavioral algorithms to identify
patients in need of intensive monitoring during anti-tuberculosis therapy may reduce this risk.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.* Corresponding author. Tel.: +1 410 366 1807; fax: +1 410 955 1836.
E-mail address: mkunihol@jhsph.edu (M.H. Kuniholm).
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52 M.H. Kuniholm et al.Figure 1 Republic of Georgia.Introduction
Although roughly one third of the human population is chroni-
cally infected with Mycobacterium tuberculosis,1 the distri-
bution of infections is far from uniform. Sub-Saharan Africa,
Asia, and Eastern Europe have the highest prevalence and
incidence rates worldwide,2 and are the areas where the
World Health Organization (WHO) Directly Observed Therapy
Short-Course (DOTS) program for tuberculosis control has
been most vigorously implemented. Although highly effec-
tive,3 several shortcomings have recently been identified in
the DOTS program.4 One of these identified shortcomings is
the failure of first-line DOTS treatment regimens in difficult-
to-treat populations, e.g., HIV co-infected patients, patients
infected with multidrug-resistant M. tuberculosis strains,
and other patients with special needs.
Patients with increased susceptibility to the hepatotoxic
effects of first-line treatment regimens represent special
populations and need to be identified prior to therapy initia-
tion and monitored more carefully than the general popula-
tion of M. tuberculosis infected patients. Unfortunately,
although three of the first-line drugs, rifampin, pyrazina-
mide, and isoniazid, are known to be hepatotoxic,5—9 the
patient characteristics that confer greater risk of treatment-
associated liver injury are poorly understood. Older age,10,11
concurrent or chronic alcohol use,12—15 hepatitis C,16 hepa-
titis B,17 and HIV16 virus infections have been found to
increase the risk of hepatotoxicity in some studies, but
non-significant associations for all of these putative risk
factors have also been reported.5,14,15,18—23 Until definitive
studies are conducted, caution suggests that patient popula-
tions should be screened for the above-mentioned charac-
teristics and monitored carefully following initiation of
therapy.
Many countries of the former Soviet Union have experi-
encedmajor increases in tuberculosis incidence over the past
fifteen years,2,24 and are attempting to control epidemics of
HIV, hepatitis B, and hepatitis C viruses with limited health-
care resources. Georgia is situated south of the Russian
Federation in the Caucasus region between the Black and
Caspian Seas (see Figure 1), and currently faces major con-
current epidemics of tuberculosis,25—27 hepatitis B,28,29 and
hepatitis C.28—31 WHO estimates suggest that tuberculosis
incidence is 83 cases per 100 000 person-years, and 16% of
new tuberculosis cases are multidrug-resistant in Georgia.32
Research studies have also found multidrug-resistant M.
tuberculosis strains to be common in Georgia,27,33 and an
evaluation of the Georgian DOTS program in the mid-1990s
suggested that 25% of individuals who begin anti-tuberculosis
therapy regimens will not complete them.34 While this study
did not evaluate the reasons for therapy interruption among
the Georgian patients, a recent study from Russia has sug-
gested that difficulty tolerating anti-tuberculosis therapy
because of co-morbid illnesses such as HIV and viral hepatitis
is common.35
Despite its potential effect on improving tuberculosis
treatment completion rates (through careful monitoring
and treatment adjustment when indicated), serologic
screening for hepatitis B, hepatitis C, and HIV viruses is
not routine practice among Georgian tuberculosis clinics
because of limited resources and the scarcity of diagnostic
capabilities within tuberculosis hospitals. In this study, weused behavioral and biomarker data collected between Octo-
ber 1997 and June 1998 in three Georgian in-patient tuber-
culosis hospitals to describe the prevalence and risk factors
for three putative viral risk factors for anti-tuberculosis
therapy-induced hepatotoxicity. We additionally assessed
the ability of simple questionnaire algorithms to accurately
predict infection with HCV and HBV to determine whether
this screening mechanism could identify subsets of patients
who are in need of intensive monitoring during anti-tuber-
culosis therapy.
Materials and methods
Study population
Between October 1997 and June 1998, we recruited indivi-
duals at in-patient tuberculosis hospitals as part of an HIV/
AIDS surveillance project conducted by the Georgian AIDS and
Clinical Immunology Research Center.28 Recruited individuals
were between the ages of 18 and 65 and were patients in
hospitals in the Georgian cities of Tbilisi, Batumi, and Poti.
Subjects were enrolled into the study if they gave their
informed consent to answer a confidential questionnaire,
be tested for HIV, HCV, and HBV, and receive the results of
these tests along with appropriate counseling. The research
protocol was reviewed and approved by institutional review
boards at the AIDS and Clinical Immunology Research Center
in Tbilisi, Georgia and the Johns Hopkins Bloomberg School of
Public Health, Baltimore, Maryland, USA.
Behavioral questionnaire
Recruited individuals who agreed to participate in the study
were interviewed confidentially by trained interviewers
regarding their clinical and demographic characteristics,
history of drug use, and sexual behaviors. After the interview
data were collected they were transferred to a Microsoft
Access database for archive and analysis.
Laboratory methods
Blood samples drawn from participating individuals were
assayed for antibody to HIV-1 with the Abbott Recombinant
Hepatitis C, hepatitis B, and HIV among Georgian TB patients 53
Table 1 Characteristics of the study population (N = 300)
Characteristic Number %
City of residence
Tbilisi 245 81.7
Poti 32 10.7
Batumi 23 7.7
Gender
Male 242 80.7
Female 58 19.3
Age
18—27 years 95 31.7
28—37 years 126 42.0
38 years 79 26.3
Education
Primary 38 12.7
Secondary 173 57.7
University 89 29.7
Blood transfusion
No 287 95.7
Yes 13 4.3
Ever injection drug use
No 277 92.3
Yes 23 7.7
Ever prison
No 278 92.7
Yes 22 7.3
Ever male homosexual contact
No 281 93.7
Yes 19 6.3
Age at first sexual contact
18 years 85 28.3
19—21 years 120 40.0
22 years 95 31.7
Number of sex partners in last 2 years
0—1 partners 113 37.7
2—3 partners 150 50.0
4 partners 37 12.3HIV-1 assay (Abbott Laboratories, Abbott Park, IL, USA).
Blood samples reactive for HIV-1 were confirmed using a
licensed Western blot assay (DuPont Co, Willmington, DE,
USA). Antibody to HCV was assessed using the Ortho HCV
Version 3.0 ELISA (Ortho Diagnostics Systems, Raritan, NJ,
USA). Hepatitis B surface antigen (HBsAg) and core antibody
(anti-HBcore) were assessed using Auszyme Monoclonal and
Corzyme assays (Abbott Laboratories, Abbott Park, IL, USA).
All laboratory testing was conducted at the AIDS and Clinical
Immunology Research Center in Tbilisi, Georgia.
Statistical methods
We calculated descriptive statistics for laboratory results and
questionnaire variables. We used bivariate and multivariable
logistic regression models to evaluate the association of
demographic, drug use history, and sexual history variables
with HCV and HBV seropositivity. We defined individuals
testing positive for either anti-HBcore or HBsAg to be HBV
positive. We used bivariate analysis to evaluate city of
residence and age-group associations, and multivariable
analysis, with all evaluated variables in a single model, to
evaluate all other associations. Too few individuals were
infected with HIV to conduct a statistical assessment of
HIV risk factors.
For our assessment of the ability of questionnaire combi-
nation algorithms to accurately predict viral infection status,
we constructed two- and three-questionnaire item combina-
tions and divided the number of individuals reporting yes to
any of the questionnaire items in the combination by the
number of individuals serologically diagnosed with HCV or
HBV infection. This quotient then reflected the sensitivity of
the questionnaire item combination compared to the gold
standard of serology. All analyses were conducted using SAS
9.1 (SAS Institute, Cary, NC, USA).
Results
Demographic, drug use history, and sexual history variables
are listed in Table 1. Most patients were male and were
recruited from hospitals in Tbilisi. Patients were most often
in their thirties and most had completed secondary school.
Histories of blood transfusion, prison, and injection drug use
were relatively rare, although sexual activity in the past two
years was not.
Two (0.7%) of the 300 surveyed individuals were HIV posi-
tive, 13 (4.3%) were HBsAg positive, 26 (8.7%) were anti-
HBcore positive, and 27 (9.0%) were positive for either HBsAg
or anti-HBcore. Thirty-six (12.0%) were HCV positive. One of
the two HIV positive individuals was HCV co-infected, and six
individuals were positive for both HCV and HBV. The two HIV
positive individuals were both male, one had received a blood
transfusion and the other had injected illicit drugs.
Risk factors for HCV and HBV seropositivity are listed in
Table 2. In bivariate analysis, neither HCV nor HBV seropre-
valence differed significantly by city of recruitment or gen-
der. In multivariable adjusted analysis, having a university-
level education was protective against the presence of HCV,
but not against the presence of HBV. Both a history of blood
transfusion and a history of injection drug use were highly
significant risk factors for both HCV and HBV. Having been in
prison was a significant risk factor for HCV, but not for HBV.Older age at first sexual contact was significantly protective
against the presence of HBV, while having four or more sexual
partners in the past two years was a significant risk factor for
HBV.
Table 3 shows the sensitivity of two-questionnaire item
combinations to predict HCV and HBV status as diagnosed by
serology. As seen in the first part of Table 3 (HCV), three two-
questionnaire item combinations predicted HCV status 61.1%
of the time. Inclusion of a third questionnaire item to form
the algorithm ‘‘Did you ever inject drugs?; Did you have your
first sexual contact at 18 years of age?; Did you ever have a
blood transfusion?’’ increased the ability to predict HCV
serostatus to 72.2%.
As seen in the second part of Table 3 (HBV), one two-
questionnaire item combination predicted HBV status 74.1%
of the time. Inclusion of a third questionnaire item to form
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Table 2 Risk factors for HCV and HBV seropositivity (N = 300)
Variable HCV HBV
OR* 95% CI OR* 95% CI
City of residence
Tbilisi 1.0 1.0
Poti 0.71 0.21, 2.49 1.61 0.51, 5.04
Batumi 0.66 0.15, 2.94 1.69 0.46, 6.17
Gender
Male 1.0 1.0
Female 0.82 0.35, 1.90 0.82 0.32, 2.14
Age
18—27 years 1.0 1.0
28—37 years 1.11 0.49, 2.52 1.04 0.40, 2.70
38 years 0.98 0.39, 2.50 1.23 0.44, 3.43
Education
Primary 1.0 1.0
Secondary 0.46 0.13, 1.66 1.09 0.13, 9.20
University 0.04 0.00, 0.55 0.84 0.20, 3.66
Blood transfusion
No 1.0 1.0
Yes 12.37 2.52, 60.56 14.02 2.51, 78.29
Ever injection drug use
No 1.0 1.0
Yes 18.26 5.37, 62.12 12.72 3.57, 45.29
Ever prison
No 1.0 1.0
Yes 4.83 1.23, 18.97 1.28 0.29, 5.79
Ever male homosexual contact
No 1.0 1.0
Yes 0.62 0.11, 3.43 4.16 0.91, 18.96
Age at first sexual contact
18 years 1.0 1.0
19—21 years 1.39 0.49, 3.94 0.54 0.17, 1.72
22 years 0.54 0.13, 2.20 0.11 0.02, 0.65
Number of sex partners in last 2 years
0—1 partners 1.0 1.0
2—3 partners 0.45 0.14, 1.49 0.55 0.14, 2.12
4 partners 1.61 0.43, 6.00 4.45 1.19, 16.70
HCV, hepatitis C virus; HBV, hepatitis B virus; OR, odds ratio; CI, confidence interval.
* ORs are adjusted for: city, gender, age group, education, blood transfusion, injection drug use, prison, male homosexual contact, age at
first sexual contact, and number of sex partner variables.the algorithm ‘‘Did you ever inject drugs?; Did you have your
first sexual contact at18 years of age?; Have you had4 sex
partners in the past two years?’’ increased the ability to
predict HBV status to 85.2%.Discussion
Hepatotoxicity is a common sideeffect associatedwith the use
of many therapeutic agents.8,35 Drug-related hepatotoxicity
Hepatitis C, hepatitis B, and HIV among Georgian TB patients 55
Table 3 Sensitivity (%) of two-item questionnaire combinations to detect serologically confirmed HCV and HBV infections
Primary
education
Blood
transfusion
Injection
drug use
Prison 18 years
at first sex
HCV
Blood transfusion 52.8
Injection drug use 55.6 58.3
Prison 44.4 41.7 52.8
18 years at first sex 52.8 55.7 61.1 61.1
4 sex partners 44.4 38.9 61.1 41.7 58.3
HBV
Blood transfusion 33.3
Injection drug use 55.6 48.2
Prison 44.4 33.3 44.4
18 years at first sex 63.0 63.0 74.1 63.0
4 sex partners 55.6 55.6 63.0 59.3 70.4
HCV, hepatitis C virus; HBV, hepatitis B virus.of antiretroviral therapy for HIV infection is more frequent
among patients who are co-infected with hepatitis viruses.36
Although some studies examining the role of viral hepatitis
co-infection on adverse events following anti-tuberculosis
therapy have produced conflicting results, countries of the
former Soviet Union, which are facing serious epidemics
of both tuberculosis and viral hepatitis, should exercise
caution and carefully monitor their patients for drug-asso-
ciated hepatotoxicity.
Our study found that HIV infection was rare but HBV and
HCV infections were common among Georgian tuberculosis
patients. High and increasing prevalence of HCV has been
reported among both tuberculosis patients and blood donors
in Georgia between 1998 and 2001,25,29,30 but this study is the
first to indicate that HBV is a significant problem among
patients with tuberculosis in Georgia.
This study indicates that injection drug use and blood
transfusions were major risk factors for both HCV and HBV,
and that spread of HCV was additionally common among
prisoners, even after adjusting for injection drug use. These
results are consistent with those of Richards et al.25 with
regard to the spread of HCV in prisons but differ in finding
that a history of blood transfusion and injection drug use
were both associated with HCV infection. Routine screening
of the Georgian blood supply for HCV was initiated in
1997,28,29 so current blood transfusions may be less likely
to transmit HCV than those conducted prior to this time. Our
results also suggest that younger age of sexual initiation and
multiple sex partners are significant risk factors for the
acquisition of HBV.
Our evaluations of simple two- and three-question beha-
vioral algorithms suggest that HBV can be predicted in many
patients who respond in the affirmative to any one of three
simple questions. These data should be of interest to tuber-
culosis clinicians, since they represent a simple and inexpen-
sive screening tool to identify patients who may be at
increased risk of hepatotoxic side effects to anti-tuberculosis
drugs. The three-questionnaire item algorithm to predict
HCV status was less sensitive than that of the HBV algorithm,
and additionally was dependent on receipt of blood transfu-
sion, a risk factor that may currently be of less significance in
Georgia. It is important to note however that the proposedalgorithms, while valid for Georgia and countries with simi-
larly propagated HCVand HBVepidemics, may not be valid for
countries with epidemiologically distinct epidemics.
Georgia is just one of many countries in the former Soviet
Union struggling to control its burgeoning tuberculosis pro-
blem. Successful treatment of tuberculosis patients with
viral hepatitis and HIV co-infection will be a challenging
task. However, it may be useful to utilize behavioral algo-
rithms to identify which patients are at highest risk of drug
toxicity in conjunction with serologic screening of high risk
tuberculosis patients for HCV, HBV, and HIV infection. Careful
clinical and laboratory monitoring, and treatment adjust-
ment as needed, will also be necessary to avert serious
hepatotoxicity in these patients.
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